ArticleEndocrine2026
The effectiveness of levothyroxine starting doses after thyroidectomy is compromised by early body variations occurring after surgery.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDosing levothyroxine (LT4) in athyreotic patients after total thyroidectomy may appear straightforward to manage. However, robust evidence to guide therapy remains lacking. This study aimed to provide further information on the efficacy of fixed, weight-adjusted LT4 dosing initiated immediately after surgery. MATERIALS: Consecutive patients were enrolled at a single institution applying a standardized postoperative protocol: all cases initiated LT4 therapy immediately postoperatively at dose of ~1.6 mcg/kg, undergo their thyroid function test after six weeks, and receive subsequent dose adjustments until the target is reached.
resultsForty-eight patients met the inclusion criteria. The median LT4 starting dose was 100 mcg per day and 1.56 mcg/kg of body weight per day. At the first follow-up, 16 (33.3%) patients were at target. Over follow-up, the overall median time-to-target was 4 months. The 32 patients who reached the target later included 15 patients showing a decreased LT4 requirement and 17 patients with an increased LT4 need. The correlation analysis between body weight and LT4 dose revealed significant negative association between LT4 dose and weight variation (R² 0.18). In the multiple linear regression body weight and comorbidities were positively associated with LT4 dose on target, while age showed a negative association.
conclusionsEarly postoperative weight changes influence significantly LT4 dose requirements, and age and comorbidities provided additional predictive value. These findings highlight the need for early follow-up and LT4 titration in patients not at target after initial evaluation.
Indexed as
Identifiers
42043746What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.